After generics, which are copies of chemical medicines, "copies" of already patented biologics (biosimilars) are entering the biologics market and competing with their originators. Many uncertainties remain regarding the development of this newly emerging market, and the ability of biosimilars...

This thesis aims to undertake an economic analysis of private medical practice while stressing on elements, which in our view, remain unsaid or unrecognised. It is about an institutional analysis, based on the historic and social embedding of the health. After presenting the specificities of...

In cost-utility analysis results are often processed in terms of QALY (Quality Adjusted Life Year). The duration of a given health state is weighted with a coefficient calculated based on its associated quality of life. Using such an indicator assumes two things: knowing the health state of the...